Previous Article | Next Article ![]()
Journal of Virology, April 1999, p. 3236-3245, Vol. 73, No. 4
Children's Memorial Institute of Education
and Research1 and Departments of
Pediatrics2 and
Microbiology-Immunology,5 Northwestern
University Medical School, Chicago, Illinois 60614; Laboratoire
de Génétique Moléculaire des Interactions
Protéiques, INSERM U332, ICGM, Université Paris V, 75014 Paris, France3; and Communication
Research Laboratory, Kansai Advanced Research Center, Kobe,
Japan4
Received 11 August 1998/Accepted 26 December 1998
Cell cycle G2 arrest, nuclear localization, and cell
death induced by human immunodeficiency virus type 1 Vpr were examined in fission yeast by using a panel of Vpr mutations that have been studied previously in human cells. The effects of the mutations on Vpr
functions were highly similar between fission yeast and human cells.
Consistent with mammalian cell studies, induction of cell cycle
G2 arrest by Vpr was found to be independent of nuclear localization. In addition, G2 arrest was also shown
to be independent of cell killing, which only occurred when the mutant Vpr localized to the nucleus. The C-terminal end of Vpr is crucial for
G2 arrest, the N-terminal Human immunodeficiency virus type 1 (HIV-1) protein R (Vpr) is a 15-kDa virion-associated protein which is
conserved among HIV-1, HIV-2, simian immunodeficiency virus (SIV),
and other lentiviruses (35, 45), suggesting an important
role of Vpr in the viral life cycle. Studies of SIV of macaques
(SIVmac) with defective vpr also indicate
the importance of Vpr. Some of the rhesus monkeys infected with
vpr-defective SIVmac either do not progress
to AIDS or show a slower progression of the disease (11, 16,
22). When vpr and vpx, a second gene
homologous to vpr in SIVmac, are both
defective, infected rhesus monkeys have a low titer of virus and do not
progress to AIDS (11, 45). In chimpanzees and one human
subject infected with an HIV-1 strain containing a mutant, nonfunctional Vpr protein, the Vpr protein reverted to the wild-type sequence during the course of the infection, indicating that there is
strong selection for Vpr during HIV-1 infection (12).
When assayed in cell culture systems, Vpr shows multiple activities.
Vpr activates viral replication (25, 26) and induces changes
of cell morphology that mimic cell differentiation (24). It
prevents cell proliferation by arresting transfected human cells in the
G2 phase of the cell cycle (14, 19, 38, 39), where the replication of HIV is increased (12, 48). The
expression of HIV Vpr in transfected human cells ultimately causes cell
death through apoptosis (1, 43) and/or cytopathic effects
(48). These effects of Vpr are highly conserved among
eukaryotes, since Vpr also causes G2 arrest, changes of
cell morphology, and cell death in fission yeast
(Schizosaccharomyces pombe) cells (50, 51, 55).
Vpr also promotes transport of the preintegration viral complex into
the nucleus and thus helps HIV-1 to infect nondividing cells (4,
15, 46). When Vpr is expressed alone in mammalian cells, it is
localized to the nucleus and often found predominately at the nuclear
membrane. In this report, we show that Vpr is localized to the nucleus
of S. pombe cells, just as it is in mammalian cells with the
same predominate localization at the nuclear membrane (46).
The processes affected by Vpr, cell cycle, nuclear localization, and
cell death, are highly conserved among eukaryotes, and studies with
yeast cells have been instrumental in the molecular dissection of these
processes (reviewed in reference 53). With regard to
the cell cycle, the Cdc2 cyclin-dependent kinase, which determines the
onset of mitosis in all eukaryotic cells, is functionally interchangeable between the fission yeast and human Cdc2 proteins (23). An illustration of the conservation of the Vpr-induced G2 arrest is that Vpr induces G2 arrest in both
fission yeast and human cells by inhibitory phosphorylation of Cdc2
(8, 14, 19, 38, 50, 54). Similarly, nuclear
localization is highly conserved between mammalian and
budding yeast cells with human nuclear transport factors
functional in budding yeast (9, 46). The classical pathway
for nuclear localization initiates with binding of the nuclear
localization sequence (NLS) to importin In this study, we examined in fission yeast the effect of a collection
of vpr mutations which have previously been characterized for their effects on G2 arrest in human cells (2,
42). One goal of this study was to determine if the mutations
have the same effect on G2 arrest in fission yeast as they
do in human cells. If there is a strong correlation between the
effects of the Vpr mutations in yeast and human cells, this finding
would support using yeast in certain functional studies of Vpr. A
second goal of this study was to determine if the vpr
mutations have differential effects on the multiple activities of
vpr which, in yeast, include G2 arrest, cell
killing, and nuclear localization. Finding a mutation with a large
effect on one function of vpr with little or no effect on
another would suggest that Vpr uses different pathways for these
two effects. The availability of these mutations would then help
in analyzing the different pathways utilized by vpr for
these multiple functions.
One ultimate goal of this study is to contribute to the development of
the yeast system as a means to address the role of multiple Vpr
activities during HIV infection and pathogenesis. The existence of
multiple Vpr activities in cell culture assays and numerous sequence
variants of Vpr in patients raises the question of whether all of these
activities are of equal importance to the virus. It may be that under
certain conditions, one or more of the activities is not required for a
normal viral life cycle and that most of the Vpr quasispecies under
these conditions do not have that activity. One approach to defining
the role of multiple Vpr activities in human infections is to develop a
structure-function map of Vpr to allow prediction of function from the
DNA sequence. Although a number of studies have focused on defining the
functional domains of Vpr (7, 30-32, 49), the large extent
of Vpr sequence variation (quasispecies) in infected patients makes
this characterization tedious and almost impossible. It is unlikely
that a sufficiently detailed structure-function map of Vpr will be
available any time soon to allow full and accurate predictions of Vpr
activities from sequence data alone. The comparative ease of
determining Vpr activities in yeast suggests the alternative approach
of cloning Vpr variants from patients into yeast cells to determine the
activities of each Vpr variant. The study reported here supports the
feasibility of this approach.
Yeast strains and media.
S. pombe SP223
(h Cloning of the vpr gene into S. pombe
expression vectors pYZ1N and pYZ3N-GFP.
The pYZ1N and pYZ3N-GFP
vectors have already been described (52). Briefly, these two
vectors are derivatives of the pREP1N vector we used to express
vpr in previous studies (51, 55). They all
contain the same nmt1-inducible promoter and were designed to allow positive selection of gene insertions (both vectors) and
fusion to the green fluorescent protein (GFP)-encoding gene (pYZ3N-GFP)
for in vivo analysis of gene expression. Expression of vpr
in the pYZ1N plasmid gives the same phenotypic changes as reported
previously for expression in the pREP1N vector (51, 52, 55).
Thirteen independent vpr point mutations, which were derivatives of wild-type vprLAI and initially
studied for their effects in human cells (42), were used in
this study. Four deletion mutants, also derivatives of wild-type
vprLAI, have been described previously
(2). These vpr genes were amplified by PCR as
described previously (51) using PCR primers VPRNde
(GAGGCATATGGAACAAGCCCCAGAAGACC) and VPRBamWT
(GGCGGATCCCTAGGATCTACTG). The digested PCR product was
inserted at the NdeI and BamHI sites of the pYZ1N
vector. The vpr genes were fused in frame with GFP by PCR
amplification using the SacI
(ACAGACCGCGGATATGGAAAAGCCCCAGAAGACC) and VPRBam primers and
inserting the digested PCR product into the SacII and
BamHI sites of pYZ3N-GFP. The ligation mixtures were
transformed into Escherichia coli, and colonies containing
plasmids with vpr inserts were identified as colorless
colonies on
5-bromo-4-chloro-3-indolyl- Measurement of cell cycle G2 arrest.
The flow
cytometry procedure used to measure cell cycle G2 arrest
was performed essentially as described previously (51), with
some minor modifications. Briefly, in order to quantify the extent of
G2 arrest induced by HIV-1 Vpr, cells were taken from an
active, log-phase, thiamine-containing culture (in the range of 1 × 107 to 5 × 107 cells per ml), washed
three times with distilled water, and used to start a thiamine-free
culture at a density of 2 × 105 cells per ml at
30°C with shaking (200 rpm). Cells were collected 40 h after the
culture was started, and the DNA content of the cells was determined by
FACScan using Cell-fit software (Becton Dickinson). The extent of
Vpr-induced G2 arrest was expressed as the percentage of
G1 cells in the vpr-repressing cells that shifted to the G2 phase of the cell cycle in
vpr-expressing cells. All of the data presented here are
averages (with standard deviations) of three independent experiments
and are expressed as a ratio of the G2 arrest of mutant
vpr to that of wild-type vpr. Ratios of greater
than one indicate increased induction of G2 arrest, and
ratios of less than one indicate reduced G2 arrest compared to wild-type Vpr.
Measurement of cell survival.
Colony-forming ability was
used as a quantitative measurement of Vpr-induced cell death as
previously described (55). Briefly, S. pombe
cells containing the pYZ1N::vpr constructs were
prepared as described above for measurement of G2 arrest.
An aliquot of each vpr-expressing or
vpr-repressing culture was collected 18 h after
vpr gene induction and plated onto thiamine-containing selection (EMM) plates. Numbers of CFU were calculated from the number
of colonies that grew on the plates as a percentage of the number of
cells originally plated, corrected by the plating efficiency of
vpr-repressed cells. The plating efficiency of
vpr-repressed cells was determined for 18-h
thiamine-containing cultures by plating on thiamine-containing EMM
selection plates and ranged from 100 to 40%.
Nuclear localization.
Cultures of cells with plasmids
expressing GFP or the GFP-Vpr fusion were prepared as described above
for measurement of G2 arrest. Cellular localization was
determined 18 to 24 h after vpr gene induction by
fluorescence microscopy on an Olympus BH2-RFL microscope using the blue
filter combination with the EY-455 supplemental exciter filter.
Secondary-structure analyses of Vpr.
The secondary
structures of Vpr were analyzed by nnpredict software, which predicts a
secondary-structure tendency for each residue in an amino acid sequence
based on a two-layer feedforward neural network (21). These
structural predictions are generally consistent with the tertiary model
proposed recently for Vpr based on circular-dichroism and nuclear
magnetic resonance (NMR) data (28, 40). The diagram of
Vpr's tertiary structure was generated by using the RasMol v. 2.6 program (41) on the coordinates provided by Ziwei Huang
(28).
Vpr proteins from viral variants NL4-3 and LAI have similar effects
on G2 arrest and cell killing.
Wild-type
VprLAI, which is the parent of all of the mutant Vpr
proteins used in this study, differs at four amino acids (Y15H, S28N,
N41G, and R85Q) from VprNL4-3, which was used in previous fission yeast studies. Figure
1 shows that
VprLAI and VprNL4-3 have similar effects on
fission yeast with respect to G2 arrest and cell killing.
Vpr-induced cell cycle G2 arrest was measured by flow
cytometry and determination of the septation index. Flow cytometry
analysis measures the percentage of G1 cells when
vpr is repressed that shift to the G2 phase in
vpr-expressing cells. This quantitative measurement of
Vpr-induced G2 arrest showed that 74.4% ± 7.8% of the
VprLAI G1 cell population shifted to G2 (Fig. 1A), compared to 71.5% ± 14.8% of the
VprNL4-3 cell population (data not shown;
51). Thus, both Vpr variants induced similarly high
levels of G2 arrest in fission yeast. The septation index assay was also used to compare the abilities of the two Vpr variants to
inhibit cell division. This assay measures the percentage of cells in a
population that contains septa, an indication of mitotic cell division
(51). Both vpr-repressing cultures maintained a
normal septation index (11.0% ± 0.5% and 11.5% ± 0.6% for
VprNL4-3 and VprLAI, respectively), indicating
normal and actively growing cells, but only 5.2% ± 1.0% and 3.5% ± 0.5% of septa were observed in the vpr-expressing cultures
18 h after vpr induction.
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Mutational Analysis of Vpr-Induced G2
Arrest, Nuclear Localization, and Cell Death in Fission Yeast
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-helix is important for
nuclear localization, and a large part of the Vpr protein is
responsible for cell killing. It is evident that the overall structure
of Vpr is essential for these cellular effects, as N- and C-terminal deletions affected all three cellular functions. Furthermore, two
single point mutations (H33R and H71R), both of which reside at the end
of each
-helix, disrupted all three Vpr functions, indicating that
these two mutations may have strong effects on the overall Vpr
structure. The similarity of the mutant effects on Vpr function in
fission yeast and human cells suggests that fission yeast can be used
as a model system to evaluate these Vpr functions in naturally
occurring viral isolates.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
, also known as karyopherin
. The NLS-importin
complex interacts with importin
, and this
complex then binds to nuclear porins, components of the nuclear pore,
for translocation into the nucleus (13). Vpr does not itself
contain an NLS, but it has recently been shown that Vpr binds to
importin
from either budding yeast or human cells to stabilize the
binding of an NLS to a different site on importin
(37,
46). More recently, it has been suggested that some aspects of
apoptosis are conserved between mammalian and fission yeast cells. Four
proteins (Bak, Bax, Ced4, and Vpr) which induce apoptosis in mammalian
cells or nematodes also induce death in fission yeast cells with
changes in nuclear morphology characteristic of apoptosis (17, 18,
20, 55). Given the high degree of conservation for the
G2-mitosis transition of the cell cycle, nuclear
localization, and cell death, Vpr almost certainly exerts these three
effects by interacting with highly conserved components of the cellular
machinery. Fission yeast is then likely to be an excellent model system
in which to study these functions of Vpr.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
ade-216 leu1-32 ura4-294) was used as the
host in this study. All of the methods used here for cell cultures, induction of vpr gene expression under the control of the
nmt1 promoter, and cell plating have been described
previously (51, 54, 55).
-D-galactopyranoside (X-Gal)-containing Luria-Bertani agar plates (6). The
insertions were initially identified by restriction enzyme digestion
and PCR. The presence of the correct mutation in each clone was
confirmed by complete nucleotide sequencing of the insert using an ABI
377 DNA Sequencer (The Perkin-Elmer Corp., Norwalk, Conn.). All of the
vpr-containing plasmids were expressed in the SP223 fission yeast strain to examine G2 arrest, nuclear localization,
and cell death.
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (37K):
[in a new window]
FIG. 1.
Effects of VprLAI on G2 arrest,
cell survival, and nuclear localization in fission yeast. (A) Flow
cytometric analyses 40 h after transfer to medium with
(vpr repressed) or without (vpr expressed)
thiamine, showing the shift of G1 cells in the medium with
thiamine (+T) to the G2 stage of the cell cycle in medium
without thiamine (
T). (B) Qualitative assay for cell killing by Vpr.
The plate with thiamine at the top represses the nmt1
promoter, and cells form normal-size colonies after incubation for 3 to
4 days. Cells with the VprNL4-3 plasmid (a) are on the left
side, and cells with the VprLAI plasmid (b) are on the
right. On the plate without thiamine shown at the bottom, the vpr gene is induced, and
both VprNL4-3 and VprLAI prevent the formation
of normal-size colonies. (C) The morphological changes induced by
VprLAI differ somewhat from those induced by
VprNL4-3. The cultures with thiamine for both
VprNL4-3 (a) and VprLAI (b) show the normal
Calcofluor staining pattern, with weak overall staining of the cell
wall and intense staining of the septum forming at the site of eventual
cell division. One cell in each panel shows this strong staining of the
septum. The cultures without thiamine at the bottom (vpr
expressed) both show large increases in chitin staining compared to
normal cells. However, for VprNL4-3 (a), this increased
chitin deposition occurs at the protruding ends of the cells while
cells with VprLAI have very thick chitin deposits near the
center of the cell, where the septum normally forms. (D) The
GFP-VprNL4-3 fusion protein localizes around the rim of the
nucleus and shows little overlap with nuclear DNA. A cell 17 h
after induction of Vpr was stained for DNA with the vital stain Hoechst
33342 (Chikashige, 1994 no. 8). The third panel, in color, shows
GFP-Vpr in the false color of red and DNA staining in the false color
of green with little overlap between the two colors.
Vpr proteins from viral variants NL4-3 and LAI induce cell morphological changes with subtle differences. Vpr induces morphological changes including gross enlargement and irregular shapes in mammalian cells (24). Gross enlargement and irregular protruding structures were also observed when VprNL4-3 was expressed in fission yeast (51). These yeast cells are generally two to three times larger than normal cells. Moreover, the protruding structures induced on the cells by Vpr correlate with sites of increased chitin biosynthesis in the cell wall. Multiple septa were found in some of the irregularly shaped cells (55) (Fig. 1Ca). Gross enlargement of cells and increased chitin biosynthesis were also found when VprLAI was expressed in yeast. Interestingly, however, neither the irregular protruding structures nor localized accumulation of chitin in the cell wall was found in the vprLAI-expressing cells. Instead, the chitin accumulation was found predominantly in the septal area (Fig. 1Cb).
GFP-Vpr fusion protein localizes to the nuclear rim. To determine the cellular localization of Vpr in fission yeast, the vpr gene was fused to the GFP-encoding reporter gene and expressed from the nmt1 promoter in fission yeast cells. As a control, the GFP-encoding gene alone was expressed from the nmt1 promoter. In thiamine-containing medium, cells with either GFP or the GFP-Vpr fusion had no green fluorescence (data not shown). When the nmt1 promoter was induced with thiamine-free medium, cells with the gfp gene alone had green fluorescence dispersed throughout the cells with obvious fluorescence in both the nuclear and cytoplasmic compartments (Fig. 2Ba). The cells with GFP alone remained normal, with no morphological changes, G2 arrest, or cell death. In contrast, cells with the GFP-Vpr fusion had intense green fluorescence around the nucleus at the nuclear rim with little labelling of the cytoplasm (Fig. 1D and 2Bb). The GFP-Vpr fusion protein retains Vpr functions, since it induces morphological changes, G2 arrest, and cell death (data not shown). As the fusion protein is functional, the localization of the GFP-Vpr fusion protein most likely represents the cellular localization of Vpr. In a two-color representation with GFP in the arbitrary color of green and DNA in the arbitrary color of white (Fig. 1Da), the combination of the two colors in the third panel shows that there is little overlap of GFP and DNA, indicating that GFP-Vpr localizes predominately at the nuclear rim, with little of the fusion actually present in the nucleus.
|
Vpr point mutations affect G2 arrest similarly in yeast and human cells. The panel of mutant Vpr proteins used in this fission yeast study come from studies of Vpr interactions with uracil DNA glycosylase (2, 42). These mutant proteins include four deletions, two from the amino terminus (N15 and N27) and two from the carboxy terminus (C63 and C77), and 13 single point mutations representing single amino acid substitutions distributed throughout the gene. The mutant vpr genes were cloned into expression vector pYZ1N. Immunoblot analysis confirmed that all of the vpr mutations were expressed in fission yeast. A 15-kDa band corresponding to the size of Vpr was detected with anti-Vpr serum for all 13 point mutations (Fig. 2A). The point mutations expressed at least as much protein as wild-type VprLAI, and the W18R, E25K, H33R, F34I, H71R, and H78R point mutant proteins had expression levels higher than that of the wild type. Thus, any reduction in activity caused by a vpr point mutation is not due to reduced protein expression. As the deletion mutant proteins may not react with the antiserum raised against a synthetic peptide representing part of Vpr (4), expression of the four deletions was measured by Northern blot analyses and shown to be similar to that of VprLAI by hybridization of an RNA blot with a vpr probe (Fig. 2Ab). Also, when expressed as fusions to GFP, all four Vpr deletion mutant proteins gave readily detectable green fluorescence, indicating that the fusion proteins were expressed at similar levels.
The mutations indicate that the carboxy terminus of Vpr is required for induction of G2 arrest in fission yeast but that other regions of the protein also play a role in G2 arrest. While the two short deletions N15 and C77 reduce the extent of G2 arrest, the longer deletions N27 and C63 eliminate G2 arrest. For the point mutations, three of six mutations in the carboxy terminus (H71R, H78R, and R88K) reduce G2 arrest. The H33R mutation is the only point mutation in the amino-terminal half of Vpr to affect G2 arrest (Table 1; Fig. 2C).
|
Vpr-induced cell death is independent of G2 arrest. More than half of the mutations in this study caused significant reductions in the amount of cell death induced by Vpr (Table 1). Three of the four deletions eliminated cell death, while the C77 deletion reduced cell death (20.9% ± 4.3%). Seven of the 13 point mutations reduced cell death to various degrees. The mutations reducing cell killing are not located in a small region of the protein, indicating that much of the Vpr protein is required for cell killing.
Five point mutations that reduced cell killing (W18R, E24G, E25K, F34I, and W54R) did not affect the ability to induce G2 arrest (Table 1). In contrast, two other mutations, H78R and R88K, showed the opposite effect, with decreased G2 arrest but unchanged levels of cell killing. Discordance between the G2 arrest and cell killing effects of these seven mutations suggests that these are the independent functions of Vpr.Nuclear localization is not required for G2 arrest. All four deletions and four of the point mutations (E25K, H33R, F34I, and H71R) affect the localization of the GFP-Vpr fusion to the nuclear rim (Fig. 2Bc to j). With GFP-VprLAI, the green labelling was restricted mostly to the rim of the nucleus, with most cells having no detectable labelling in the cytoplasm or the nucleus itself (Fig. 1D and 2Bb). In contrast, the four deletions and four point mutations had various levels of labelling in the cytoplasm, along with other differences from the labelling pattern of the GFP-VprLAI fusion protein. The N15 and C77 deletions and the H33R, F34I, and H71R point mutations caused labelling of the nuclear rim weaker than that obtained with GFP-VprLAI, while the N27 and C63 deletions and the E25K point mutation caused little or no preferential labelling of the nuclear rim. General labelling of the nucleus at various levels was seen for the N27 and C77 deletions and the four point mutations affecting nuclear localization. The N15 deletion and, to a lesser extent, the C77 deletion frequently caused a strong dot of labelling on the nuclear rim. The C63 deletion is the only mutation that nearly eliminated any specific labelling and resulted in labelling that was almost randomly distributed in the cell.
The E25K and F34I mutations indicate that nuclear localization is not required for G2 arrest, since these mutations produced levels of G2 arrest comparable to that of wild-type VprLAI, even though localization to the nuclear rim was reduced or eliminated. The E25K mutation also produced normal levels of G2 arrest in human cells (42). In contrast, other point mutations (H78R and R88K) that produced typical nuclear localization reduced the ability to induce G2 arrest in yeast, which is also consistent with the idea that nuclear localization and G2 arrest are independent functions of Vpr.Nuclear localization may be required for cell killing. The four point mutations (E25K, H33R, F34I, and H71R) and the four deletion mutations reducing or eliminating nuclear localization all significantly reduced cell killing, suggesting that nuclear localization is required for cell killing (Table 1). Analysis of more mutations for their effects on cell killing and nuclear localization is necessary to confirm this. However, if nuclear localization is required for cell killing, this series of mutations clearly establishes that nuclear localization is not sufficient for cell killing, since point mutations E24G and W54R produced the typical localization to the nuclear rim, but these two mutations significantly reduced cell-killing ability (43.1% ± 16.7% and 44.2% ± 14.1% compared to the 16.7% ± 3.6% of VprLAI).
Structural requirements for Vpr functions.
A tertiary
structure of Vpr recently proposed on the basis of NMR and
circular-dichroism data consists of helix-loop-helix domains and amino
and carboxy tails (28, 34, 40). The approximate positions of
these structural features are amino acids 1 to 16 for the amino tail,
17 to 34 for the first
-helix, 35 to 51 for the loop, 52 to 71 for
the second
-helix, and 72 to 96 for the carboxy tail. NMR studies
indicate that the second
-helix may extend several more amino acids
beyond position 71 (40). The two
-helixes in Vpr which
are indicated by circular-dichroism and NMR data are likely to interact
with each other through their hydrophobic faces (28, 40, 44,
49). The tertiary structures of the loop and the N and C tails
have not yet been reported.
-helix in the N-terminal portion of Vpr appears to be
crucial for nuclear localization. Three single substitutions (E25K,
H33R, and F34I) that reside within or near the N-terminal
-helix
reduced or eliminated localization to the nuclear rim (Fig. 2C). The
regions of Vpr required for cell killing appear to span most of the
protein. Point mutations in or near the first
-helix (W18R, E24G,
E25K, H33R, and F34I) reduce cell killing, as do the two mutations in
the second
-helix (W54R and H71R). Four of five point mutations in
the carboxy tail (H78R, S79A, R88K, and A89T) do not affect cell
killing to a significant extent, but the R90K mutation increases cell
killing. Notably, two point mutations (H33R and H71R) reduce all three
functions, G2 arrest, nuclear localization, and cell
killing, and these two mutations are at the carboxy ends of each
-helix (Table 1; Fig. 3).
|
| |
DISCUSSION |
|---|
|
|
|---|
The high degree of conservation of Vpr functions was first reported for the VprNL4-3 viral variant, which induces cell cycle G2 arrest, cell death, and localization to the nucleus in both mammalian and fission yeast cells (7, 43, 51, 55). This study shows that these effects of VprLAI, which differs at four amino acids from VprNL4-3 and which induces G2 arrest, nuclear localization, and cell death in human cells (44, 48), are essentially the same as those of VprNL4-3 in fission yeast. However, these two variants of Vpr induce morphological changes in fission yeast with subtle differences (Fig. 1C). VprNL4-3 induces unique protruding structures that correlate with an accumulation of chitin (55). While VprLAI also induces increased chitin biosynthesis, it does not induce the protruding structures with the associated accumulation of chitin, but instead, the increased chitin accumulates predominantly in the equatorial region where the multiple new cell walls (septa) are formed. While the mechanism of increased chitin biosynthesis in fission yeast and the analogous function in human cells is unknown, this subtle difference between VprNL4-3 and VprLAI observed in fission yeast raises the question of whether these two variants of Vpr also function somewhat differently in human cells.
The results obtained with the mutations in VprLAI are further evidence for the conservation of Vpr functions, since when the same mutation has been studied in human cells, the mutations almost always have similar effects in human and yeast cells. For G2 arrest, 9 of the 12 mutations show identical effects on G2 arrest in human and yeast cells (Table 1). Two of the mutations (F34I and W54R) show minor differences between fission yeast and human cells with reduced G2 arrest in human cells but no change in yeast cells. This discrepancy could be due to the differences in scoring of the G2 effect. The one exception is the R90K mutation, which produced wild-type or somewhat enhanced G2 arrest in fission yeast (1.11 ± 0.12), opposite to the decreased G2 arrest reported in mammalian cells (42). This opposite effect could be explained by differences in the interaction of R90K mutant Vpr with the homologous yeast and human target proteins with which Vpr interacts to induce G2 arrest; R90K Vpr might have a stronger interaction with the yeast protein but a weaker interaction with the human protein. This possibility can be tested when the initial target protein for the induction of G2 arrest is identified.
Vpr mutations also seem to affect nuclear localization almost identically in human and yeast cells. Four of the mutations found to reduce or eliminate localization of the GFP-Vpr fusion protein to the nuclear rim in fission yeast (E25K, F34I, H71R, and the C77 deletion) also affect nuclear localization in human cells. Vodicka et al. (46) reported that VprLAI localized to the nuclear membrane in human and budding-yeast cells, just as the fusion protein does in fission yeast. They also showed that the F34I and H71R Vpr mutant proteins do not localize to the nuclear membrane in human cells, in good agreement with the results reported here showing that the F34I mutation nearly eliminates localization to the nuclear membrane and H71R significantly reduces it. Yao et al. (49) reported that E25K and the C77 deletion produced large amounts of Vpr protein in the cytoplasm. This close agreement between human and yeast cells with respect to the effects of mutations on G2 arrest and nuclear localization suggests that most of the time results from yeast studies on a Vpr mutation will also apply to human cells.
Another indication that Vpr functions are highly conserved is that the regions of Vpr important for a function appear to be similar in human and fission yeast cells. For G2 arrest in fission yeast, point mutations in the amino-terminal end do not affect G2 arrest, with the exception of the H33R mutation discussed below. However, a number of point mutations at the carboxy terminus of Vpr affect G2 arrest. The strong influence of the carboxy terminus on G2 arrest is illustrated by pairs of nearby amino acids (H78R plus S79A and R88K plus R90K) whose mutation has opposite effects on G2 arrest. The point mutations analyzed in fission yeast then indicate that the carboxy-terminal end is particularly important for G2 arrest. The same conclusion has been reached from studies of Vpr-induced G2 arrest in mammalian cells (7, 30, 42, 48).
The regions of Vpr required for nuclear localization also seem to be
similar in human and fission yeast cells. Proline substitutions, which
disrupt
-helixes, at five different positions in the N-terminal domain of Vpr impaired nuclear localization in mammalian cells (7,
31). In fission yeast, the two N-terminal deletions and three
single substitutions (E25K, H33R, and F34I) within or near the end of
the N-terminal
-helix nearly abolished nuclear localization (Fig.
2C). Thus, the structural domain of Vpr required for nuclear localization is the same in human and fission yeast cells.
This study of Vpr mutations shows that a mutation often affects the functions of Vpr differently and suggests that some functions of Vpr are independent. In particular, four mutations (E25K, F34I, H78R, and R88K) have significantly different effects on G2 arrest and nuclear localization. The best example of this point is the E25K mutation that nearly eliminates localization to the nuclear rim without any detectable effect on the levels of G2 arrest. Similar observations in mammalian cells have led to proposals that G2 arrest and nuclear localization are independent functions mediated by two different structural domains of Vpr (10, 30, 46).
These studies in fission yeast also suggest that G2 arrest
is not required for cell killing. Comparisons between Vpr-induced cell
killing in fission yeast and human cells are limited by the small
amount of data available about the effects of Vpr mutations on the
killing of human cells. Only one mutation studied here has also been
examined in human cells, and in agreement with our observations in
fission yeast, the C77 deletion impairs both G2 arrest and
cell killing in Jurkat T cells (48). However, contrary to
our view that G2 arrest and cell killing are separate
functions of Vpr, Yao et al. (48) have suggested that
G2 arrest correlates with cell killing. In their studies,
two of four single substitutions (I63K and R80A) were shown to decrease
both G2 arrest and cell killing. In our study, decreased
G2 arrest and cell killing were also caused by two point
mutations (H33R and H71R) and all four deletions from either the N or C
terminus. However, a discordance between the effect on G2
arrest and cell killing was observed in seven single amino acid
substitutions, including four mutations at the N-terminal
-helical
region (W18R, E24G, E25K, and F34I), one mutation at the leucine-rich
domain (W54R), and two mutations at the C terminus (H78R and R88K).
These data strongly support the idea that Vpr uses different pathways
to induce G2 arrest and cell death. This idea is further
supported by our recent studies (8) showing that Vpr-induced
G2 arrest can be suppressed by a nonphosphorylatable Tyr15
mutation of Cdc2. In this mutant yeast strain, Vpr does not induce
G2 arrest, but Vpr is still able to kill cells as
efficiently as in a wild-type yeast strain. Based on this result and
the evidence from analysis of Vpr mutants, we conclude that
G2 arrest and cell death are independent functions of Vpr
in fission yeast. More mutations, particularly ones such as E25K, which
eliminates cell death but produces wild-type levels of G2
arrest in fission yeast, need to be analyzed in human cells to
determine if G2 arrest and apoptosis are independent
functions of Vpr in human cells.
In contrast to the independence of G2 arrest from nuclear localization and cell killing in fission yeast, the mutant analysis suggests that nuclear localization and cell killing are related. Mutations that impair nuclear localization (E25K, H33R, F34I, and H71R) also attenuate the ability of Vpr to kill cells, suggesting that Vpr needs to localize to the nuclear rim to be effective in the induction of cellular death. However, nuclear localization is not sufficient for cell killing. Mutations (E24G and W54R) that reduce the ability of Vpr to kill cells still cause its localization to the nuclear rim. An alternative explanation of the mutant data obtained with fission yeast is that the functional domains needed for nuclear localization and cell killing simply overlap and that, by happenstance, no mutation included in this study separated nuclear localization and cell killing. This possibility is supported by the point mutations that indicate that the cell-killing domain involves most of the Vpr protein and extends beyond the nuclear localization domain (Fig. 3b and c).
Although the point mutations suggest that the carboxy end of Vpr is
important for G2 arrest and that the N-terminal
-helix is important for nuclear localization, the deletions, in contrast, tend
to indicate that the overall structure of the Vpr protein is required
for the wild-type levels of functions. A particularly interesting
observation is that the N-terminal end of Vpr seems to have some role
in G2 arrest, since the N15 deletion reduces G2
arrest and the N27 deletion eliminates G2 arrest. This
deletion may affect G2 arrest through structural changes in
Vpr. The tertiary structures of the amino and carboxy tails of Vpr are
not known, but they might be close to each other at the end of the
protein, where they are in a position to interact with each other (Fig. 3). If the amino tail serves to hold the carboxy tail in a structure necessary for binding to the protein leading to G2 arrest,
then the amino-terminal deletions could affect G2 arrest
even if the carboxy portion contains the actual binding site. A
structural change may also explain the ability of two point mutations
(H33R and H71R) to interrupt all three functions. These two amino acids are present near the end of each proposed
-helix and may represent sites that are crucial to maintaining the overall structure required for Vpr functions. Therefore, these sites might be potential targets in
designing anti-Vpr regimens.
These studies of mutant Vpr proteins have major implications for the functions of the Vpr quasispecies present during HIV infection. Ten of the 13 point mutations examined in this study affected one or more of the three Vpr functions (G2 arrest, nuclear localization, and cell killing). Eight of these 10 point mutations had a significant effect on only one or two of these three functions while leaving the other function(s) unchanged. Vpr mutations then often have functional consequences and frequently affect only a subset of functions. Even VprLAI and VprNL4-3 had subtle differences in their induction of morphological changes in fission yeast, indicating that all Vpr variants are not functionally equivalent. These observations raise the question of whether individual Vpr quasispecies all possess identical G2 arrest, nuclear localization, and apoptosis activities. The similar effects of Vpr mutations on these activities in fission yeast and human cells indicate that the yeast system will be useful in evaluating the functional variations of naturally occurring Vpr variants.
| |
ACKNOWLEDGMENTS |
|---|
We thank Michael Emerman and Josephine Sire for their gifts of point and deletion mutant vpr genes, respectively, Ziwei Huang for providing the coordinates to generate the tertiary structure of the Vpr protein, Jun Yang for assistance in DNA sequencing, and Ram Yogev for encouragement. The HIV-1 VprNL4-3 antiserum was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, and contributed by Velpandi Ayyavoo.
This work was supported in part by funding from the Chicago Pediatric Faculty Foundation and National Institutes of Health grant 1R29-AI-40891-091 (Y.Z.).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: 2430 N. Halsted St., #218, Chicago, IL 60614. Phone: (773) 880-6608. Fax: (773) 880-6609. E-mail: yzhao{at}nwu.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Ayyavoo, V., A. Mahboubi, S. Mahalingam, R. Ramalingam, S. Kudchodkar, W. V. Williams, D. R. Green, and D. B. Weiner. 1997. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nat. Med. 3:1117-1123[Medline]. |
| 2. | Bouhamdan, M., S. Benichou, F. Rey, J.-M. Navarro, I. Agostini, B. Spire, J. Camonis, G. Slupphaug, R. Vigne, R. Benarous, and J. Sire. 1996. Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. J. Virol. 70:697-704[Abstract]. |
| 3. | Chou, P. Y., and G. D. Fasman. 1978. Empirical predictions of protein conformation. Annu. Rev. Biochem. 47:251-276[Medline]. |
| 4. | Connor, R. I., B. K. Chen, S. Choe, and N. R. Landau. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944[Medline]. |
| 5. |
Conti, L.,
G. Rainaldi,
P. Matarrese,
B. Varano,
R. Rivabene,
S. Columba,
A. Sato,
F. Belardelli,
W. Malorni, and S. Gessani.
1998.
The HIV-1 vpr protein acts as a negative regulator of apoptosis in a human lymphoblastoid T cell line: possible implications for the pathogenesis of AIDS.
J. Exp. Med.
187:403-413 |
| 6. | Cronan, J. J., M. Narasimhan, and M. Rawlings. 1988. Insertional restoration of beta-galactosidase alpha-complementation. Gene 70:161-170[Medline]. |
| 7. | Di Marzio, P., S. Choe, M. Ebright, R. Knoblanch, and N. R. Landau. 1995. Mutational analysis of cell cycle arrest, nuclear localization, and virion packaging of human immunodeficiency virus type 1 Vpr. J. Virol. 69:7909-7916[Abstract]. |
| 8. | Elder, R. T., M. Yu, M. Chen, and Y. Zhao. Tyr15 phosphorylation of Cdc2 is required for cell cycle G2 arrest induced by HIV-1 Vpr and is independent of cell death in fission yeast. Submitted for publication. |
| 9. | Fabre, E., and E. Hurt. 1997. Yeast genetics to dissect the nuclear pore complex and nucleocytoplasmic trafficking. Annu. Rev. Genet. 31:277-313[Medline]. |
| 10. | Fletcher, T. M., 3rd, B. Brichacek, N. Sharova, M. A. Newman, G. Stivahtis, P. M. Sharp, M. Emerman, B. H. Hahn, and M. Stevenson. 1996. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J. 15:6155-6165[Medline]. |
| 11. | Gibbs, J. S., A. A. Lackner, S. M. Lang, M. A. Simon, P. K. Sehgal, M. D. Daniel, and R. C. Desrosiers. 1995. Progression to AIDS in the absence of a gene for vpr or vpx. J. Virol. 69:2378-2383[Abstract]. |
| 12. | Goh, W. C., M. E. Rogel, C. M. Kinsey, S. F. Michael, P. N. Fultz, M. A. Nowak, B. H. Hahn, and M. Emerman. 1998. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat. Med. 4:65-71[Medline]. |
| 13. | Gorlich, D., and I. W. Mattaj. 1996. Nucleocytoplasmic transport. Science 271:1513-1518[Abstract]. |
| 14. | He, J., S. Choe, R. Walker, P. Di Marzio, D. O. Morgan, and N. R. Landau. 1995. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69:6705-6711[Abstract]. |
| 15. |
Heinzinger, N.,
M. Bukinsky,
S. Haggerty,
A. Ragland,
V. Kewalramani,
M. Lee,
H. Gendelman,
L. Ratner,
M. Stevenson, and M. Emerman.
1994.
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.
Proc. Natl. Acad. Sci. USA
91:7311-7315 |
| 16. | Hoch, J., S. M. Lang, M. Weeger, C. Stahl-Hennig, C. Coulibaly, U. Dittmer, G. Hunsmann, D. Fuchs, J. Müller, S. Sopper, B. Fleckenstein, and K. T. Überla. 1995. vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J. Virol. 69:4807-4813[Abstract]. |
| 17. | Ink, B., M. Zörnig, B. Baum, N. Hajibagheri, C. James, T. Chittenden, and G. Evan. 1997. Human Bak induces cell death in Schizosaccharomyces pombe with morphological changes similar to those with apoptosis in mammalian cells. Mol. Cell. Biol. 17:2468-2474[Abstract]. |
| 18. | James, C., S. Gschmeissner, A. Fraser, and G. I. Evan. 1997. CED-4 induces chromatin condensation in Schizosaccharomyces pombe and is inhibited by direct physical association with CED-9. Curr. Biol. 7:246-252[Medline]. |
| 19. | Jowett, J. B., V. Planelles, B. Poon, N. P. Shah, M.-L. Chen, and I. S. Y. Chen. 1995. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J. Virol. 69:6304-6313[Abstract]. |
| 20. | Jurgensmeier, J. M., S. Krajewski, R. C. Armstrong, G. M. Wilson, T. Oltersdorf, L. C. Fritz, J. C. Reed, and S. Ottilie. 1997. Bax- and Bak-induced cell death in the fission yeast Schizosaccharomyces pombe. Mol. Biol. Cell 8:325-339[Abstract]. |
| 21. | Kneller, D. G., F. E. Cohen, and R. Langridge. 1990. Improvements in protein secondary structure prediction by an enhanced neural network. J. Mol. Biol. 214:171-182[Medline]. |
| 22. |
Lang, S. M.,
M. Weeger,
C. Stahl-Hennig,
C. Coulibaly,
G. Hunsmann,
J. Müller,
H. Müller-Hermelink,
D. Fuchs,
H. Wachter,
M. M. Daniel,
R. C. Desrosiers, and B. Fleckenstein.
1993.
Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus.
J. Virol.
67:902-912 |
| 23. | Lee, M. G., and P. Nurse. 1987. Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 327:31-35[Medline]. |
| 24. | Levy, D. N., L. S. Fernandes, W. V. Williams, and D. B. Weiner. 1993. Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell 72:541-550[Medline]. |
| 25. |
Levy, D. N.,
Y. Refaeli,
R. R. MacGregor, and D. B. Weiner.
1994.
Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1.
Proc. Natl. Acad. Sci. USA
91:10873-10877 |
| 26. | Levy, D. N., Y. Refaeli, and D. B. Weiner. 1995. Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J. Virol. 69:1243-1252[Abstract]. |
| 27. |
Lu, Y.-L.,
P. Spearman, and L. Ratner.
1993.
Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions.
J. Virol.
67:6542-6550 |
| 28. | Luo, Z., D. J. Butcher, R. Murali, A. Srinivasan, and Z. Huang. 1998. Structural studies of synthetic peptide fragments derived from the HIV-1 Vpr protein. Biochem. Biophys. Res. Commun. 244:732-736[Medline]. |
| 29. |
Macreadie, I. G.,
L. A. Castelli,
D. R. Hewish,
A. Kirkpatrick,
A. C. Ward, and A. A. Azad.
1995.
A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects.
Proc. Natl. Acad. Sci. USA
92:2770-2774 |
| 30. | Mahalingam, S., V. Ayyavoo, M. Patel, T. Kieber-Emmons, and D. B. Weiner. 1997. Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J. Virol. 71:6339-6347[Abstract]. |
| 31. | Mahalingam, S., R. G. Collman, M. Patel, C. E. Monken, and A. Srinivasan. 1995. Functional analysis of HIV-1 Vpr: identification of determinants essential for subcellular localization. Virology 212:331-339[Medline]. |
| 32. |
Mahalingam, S.,
S. A. Khan,
R. Murali,
M. A. Jabbar,
C. E. Monken,
R. G. Collman, and A. Srinivasan.
1995.
Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation.
Proc. Natl. Acad. Sci. USA
92:3794-3798 |
| 33. |
Nie, Z.,
D. Bergeron,
R. A. Subbramanian,
X.-J. Yao,
F. Checroune,
N. Rougeau, and E. A. Cohen.
1998.
The putative alpha helix 2 of human immunodeficiency virus type 1 Vpr contains a determinant which is responsible for the nuclear translocation of proviral DNA in growth-arrested cells.
J. Virol.
72:4104-4115 |
| 34. | Piller, S. C., G. D. Ewart, A. Premkumar, G. B. Cox, and P. W. Gage. 1996. Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers. Proc. Natl. Acad. Sci. USA 93:115-115. |
| 35. | Planelles, V., J. B. Jowett, Q-X. Li, Y. Xie, B. Hahn, and I. S. Chen. 1996. Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J. Virol. 70:2516-2524[Abstract]. |
| 36. | Poon, B., J. B. Jowett, S. A. Stewart, R. W. Armstrong, G. M. Rishton, and I. S. Y. Chen. 1997. Human immunodeficiency virus type 1 vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard. J. Virol. 71:3961-3971[Abstract]. |
| 37. |
Popov, S.,
M. Rexach,
L. Ratner,
G. Blobel, and M. Bukrinsky.
1998.
Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex.
J. Biol. Chem.
273:13347-13352 |
| 38. | Re, F., D. Braaten, E. K. Franke, and J. Luban. 1995. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J. Virol. 69:6859-6864[Abstract]. |
| 39. | Rogel, M. E., L. I. Wu, and M. Emerman. 1995. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J. Virol. 69:882-888[Abstract]. |
| 40. | Roques, B. P., N. Morellet, H. de Rocquigny, H. Demene, W. Schueler, and N. Jullian. 1997. Structure, biological functions and inhibition of the HIV-1 proteins Vpr and NCp7. Biochimie 79:673-680[Medline]. |
| 41. | Sayle, R. A., and E. J. Milner-White. 1995. RASMOL: biomolecular graphics for all. Trends Biochem. Sci. 20:374[Medline]. |
| 42. | Selig, L., S. Benichou, M. E. Rogel, L. I. Wu, M. A. Vodicka, J. Sire, R. Benarous, and M. Emerman. 1997. Uracil DNA glycosylase specifically interacts with Vpr of both human immunodeficiency virus type 1 and simian immunodeficiency virus of sooty mangabeys, but binding does not correlate with cell cycle arrest. J. Virol. 71:4842-4846[Abstract]. |
| 43. | Stewart, S. A., B. Poon, J. B. Jowett, and I. S. Y. Chen. 1997. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J. Virol. 71:5579-5592[Abstract]. |
| 44. | Subbramanian, R. A., X. J. Yao, H. Dilhuydy, N. Rougeau, D. Bergeron, Y. Robitaille, and E. A. Cohen. 1998. Human immunodeficiency virus type 1 Vpr localization: nuclear transport of a viral protein modulated by a putative amphipathic helical structure and its relevance to biological activity. J. Mol. Biol. 278:13-30[Medline]. |
| 45. | Tristem, M., C. Marshall, A. Karpas, and F. Hill. 1992. Evolution of the primate lentiviruses: evidence from vpx and vpr. EMBO J. 11:3405-3412[Medline]. |
| 46. |
Vodicka, M. A.,
D. M. Koepp,
P. A. Silver, and M. Emerman.
1998.
HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection.
Genes Dev.
12:175-185 |
| 47. | Wang, B., Y. Ge, P. Palasanthiran, S. Xiang, J. Ziegler, D. Dwyer, C. Randle, D. Dowton, A. Cunningham, and N. Saksena. 1996. Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispecies in blood and plasma. Virology 223:224-232[Medline]. |
| 48. |
Yao, X.-J.,
A. J. Mouland,
R. A. Subbramanian,
J. Forget,
N. Rougeau,
D. Bergeron, and E. A. Cohen.
1998.
Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells.
J. Virol.
72:4686-4693 |
| 49. | Yao, X.-J., R. A. Subbramanian, N. Rougeau, F. Boisvert, D. Bergeron, and E. A. Cohen. 1995. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J. Virol. 69:7032-7044[Abstract]. |
| 50. | Zhang, C., C. Rasmussen, and L.-J. Chang. 1997. Cell cycle inhibitory effects of HIV and SIV Vpr and Vpx in the yeast Schizosaccharomyces pombe. Virology 230:103-112[Medline]. |
| 51. | Zhao, Y., J. Cao, M. R. G. O'Gorman, M. Yu, and R. Yogev. 1996. Effect of human immunodeficiency virus type 1 protein R (vpr) gene expression on basic cellular function of fission yeast Schizosaccharomyces pombe. J. Virol. 70:5821-5826[Abstract]. |
| 52. | Zhao, Y., R. T. Elder, M. Z. Chen, and J. Cao. 1998. Fission yeast expression vectors adapted for positive identification of gene insertion and GFP fusion. BioTechniques 25:2-4. |
| 53. | Zhao, Y., and H. B. Lieberman. 1995. Schizosaccharomyces pombe: a model for molecular studies of eukaryotic genes. DNA Cell Biol. 14:359-371[Medline]. |
| 54. | Zhao, Y., and Y. Lu. 1996. Lithium-acetate based protocol for yeast transformation, p. 63-64. In Y. M. Li, and Y. Zhao (ed.), Practical protocols in molecular biology. Science Press Ltd., New York, N.Y. |
| 55. | Zhao, Y., M. Yu, M. Chen, R. T. Elder, A. Yamamoto, and J. Cao. 1998. Pleiotropic effects of HIV-1 protein R (Vpr) on morphogenesis and cell survival in fission yeast and antagonism by pentoxifylline. Virology 246:266-276[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»